Clinicians in 25 countries prefer to use lower levels of oxygen to resuscitate preterm infants at birth
Aim This study determined current international clinical practice and opinions regarding initial fractional inspired oxygen (FiO2) and pulse oximetry (SpO2) targets for delivery room resuscitation of preterm infants of less than 29 weeks of gestation. Methods An online survey was disseminated to neo...
Saved in:
Published in | Acta Paediatrica Vol. 105; no. 9; pp. 1061 - 1066 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Norway
Blackwell Publishing Ltd
01.09.2016
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Aim
This study determined current international clinical practice and opinions regarding initial fractional inspired oxygen (FiO2) and pulse oximetry (SpO2) targets for delivery room resuscitation of preterm infants of less than 29 weeks of gestation.
Methods
An online survey was disseminated to neonatal clinicians via established professional clinical networks using a web‐based survey programme between March 9 and June 30, 2015.
Results
Of the 630 responses from 25 countries, 60% were from neonatologists. The majority (77%) would target SpO2 between the 10th to 50th percentiles values for full‐term infants. The median starting FiO2 was 0.3, with Japan using the highest (0.4) and the UK using the lowest (0.21). New Zealand targeted the highest SpO2 percentiles (median 50%). Most respondents agreed or did not disagree that a trial was required that compared the higher FiO2 of 0.6 (83%), targeting the 50th SpO2 percentile (60%), and the lower FiO2 of 0.21 (80%), targeting the 10th SpO2 percentile (78%). Most (65%) would join this trial. Many considered that evidence was lacking and further research was needed.
Conclusion
Clinicians currently favour lower SpO2 targets for preterm resuscitation, despite acknowledging the lack of evidence for benefit or harm, and 65% would join a clinical trial. |
---|---|
Bibliography: | ArticleID:APA13485 istex:143D9497D582A8A518E0A7B4C1FAD7B941C4914E ark:/67375/WNG-DVD45TWR-D ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0803-5253 1651-2227 |
DOI: | 10.1111/apa.13485 |